Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
What’s Behind Cannabis Stock HERB? (click to learn more) Eshbal Acquires a 55% Interest in Dare to Be Different Foods (click to learn more) CSE: ALEN.U — AI Meets Digital Health (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Coherus Oncology Inc CHRS

Healthcare Biotechnology
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human... see more

Current News (NDAQ:CHRS)

Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 6, 2026

Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)

GlobeNewswire January 5, 2026

Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma

GlobeNewswire December 8, 2025

Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody

GlobeNewswire November 7, 2025

Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire November 6, 2025

Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer

GlobeNewswire November 6, 2025

Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025

GlobeNewswire October 30, 2025

Coherus Oncology to Participate in Upcoming Investor Conferences

GlobeNewswire October 23, 2025

Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

GlobeNewswire October 3, 2025
View More News ››

Opinion & Analysis (NDAQ:CHRS)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:CHRS)

CHRS ANNOUNCES CLINICAL SUPPLY AGREEMENT WITH JOHNSON & JOHN

  Coherus Oncology Announces Clinical Supply Agreement to Evaluate Tagmokitug in Combination with Pasritamig...
Humanist - 6 days ago

CHRS: large volume of call options on coherus.

Investors Purchase Large Volume of Call Options on Coherus Oncology (NASDAQ:CHRS) Posted by ABMN Staff on Jan 25th...
Humanist - January 25, 2026

CHRS: IMPT PRESENTATION UPCOMING NOV 8, 2025 12-2 PM

Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) – CHS...
Humanist - October 9, 2025

Anyone heard anything about CHRS presentation yesterday?

CHRS presented yesterday at J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 5:15 p.m. Pacific Time. The presentation...
Humanist - January 14, 2025

anyone deals with cibc experienced tech difficulties TDY?

PLS LET ME KNOW .. THX 
Humanist - December 9, 2024

CHRS agrees to divest Udenyca for $558 mlns to INTAS

Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd. Coherus BioSciences...
Humanist - December 3, 2024
View more Bullboard ››

New Pacific Metals Corp

New Pacific Metals Corp

New Pacific Metals Corp., together with its subsidiaries, engages in the exploration and development of mineral properties in ...
View More »

Podcasts